IASLC/LinkedIn
Jun 19, 2025, 18:18
The safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC
International Association for the Study of Lung Cancer shared a post on LinkedIn:
“In this study, Zhao et al. evaluated the safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC. The results demonstrated its potential to become a new treatment option in this patient population.”
Title: Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial
Authors: Shen Zhao, Huaqiang Zhou, Nong Yang, Zhehai Wang, Wenjian Jin, Yuxiang Ma, Jinhui Xue, Xingya Li, Yunpeng Liu, Rui Meng, Jianying Zhou, Ying Cheng, Yongsheng Wang, Zhuang Yu, Yu Cao, Yuanyuan Zhao, Yan Huang, Wenfeng Fang, Yang Zhang, Shaodong Hong, Bo Wu, Yanxia Shi, Jingrong Cao, Mingyan Xu, Xiaoni Zhang, Longyu Hu, Bo Peng, Yunpeng Yang, Li Zhang, Hongyun Zhao
Read the Full Article.
Bo Peng
Bo Wu
cancer
Hongyun Zhao
Huaqiang Zhou
Jianying Zhou
Jingrong Cao
Jinhui Xue
Li Zhang
Longyu Hu
Mingyan Xu
Nong Yang
OncoDaily
Oncology
Rui Meng
Shaodong Hong
Shen Zhao
Wenfeng Fang
Wenjian Jin
Xiaoni Zhang
Xingya Li
Yan Huang
Yang Zhang
Yanxia Shi
Ying Cheng
Yongsheng Wang
Yu Cao
Yuanyuan Zhao
Yunpeng Liu
Yunpeng Yang
Yuxiang Ma
Zhehai Wang
Zhuang Yu
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 11, 2025, 20:42
Jul 11, 2025, 20:37
Jul 11, 2025, 20:13
Jul 11, 2025, 19:32
Jul 11, 2025, 19:23
Jul 11, 2025, 19:07
Jul 11, 2025, 18:04